



Editorial

Diagnostic challenges in CADASIL

Desafios diagnósticos no CADASIL

Hugh Stephen Markus¹ ¹ University of Cambridge, Stroke Research Group, Cambridge, United Kingdom.

Arq. Neuropsiquiatr. 2023;81:415–416.

CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) is the most common monogenic form of stroke. It results from mutations in the *NOTCH3* gene, which encodes a transmembrane receptor. Mutations are highly stereotyped and occur in the extracellular portion of the protein, and add or remove a cysteine residue resulting in disruption of a disulphide bond in one of the epidermal growth factor like (EGF) repeats. The classical features of CADASIL include migraine usually with aura, lacunar stroke, and vascular cognitive impairment and dementia.^{1–3} Other features include encephalopathy, epilepsy, depression and apathy.

The paper in this issue by Nogueira describes a cohort of 26 patients from Brazil with CADASIL.⁴ They were recruited from 6 rehabilitation hospitals. The authors nicely describe the clinical spectrum and neuroimaging features of CADASIL. They highlight that ischaemic stroke is common, as are cognitive impairment, dementia and psychiatric manifestations. CADASIL has been described in different ethnic groups throughout the world and its clinical and radiographic appearances are broadly similar in different geographical locations, although there has been a suggestion that there may be differences in some Far Eastern pedigrees, some of whom have been reported to have non-cysteine changing mutations.⁵ This study shows the pattern in Brazil is similar to that seen in other populations throughout the world.

The paper also highlights diagnostic features of CADASIL. In a patient with consistent clinical features and who often has a family history, the most useful diagnostic pointer is neuroimaging. MRI shows white matter hyperintensities which become increasingly confluent with age, and in some people lacunar infarcts and cerebral microbleeds. The pattern of WMH is characteristic with involvement of the anterior temporal pole reported in 90%.⁶ This has been shown to have a high specificity. This pattern was seen in the

Brazilian population. Other predilection sites include the external capsule which is commonly involved but is a less specific finding.⁶ The paper also highlights diagnostic difficulties, and the fact that many cases are misdiagnosed before the correct diagnosis of CADASIL is made. Three patients in the Brazilian cohort were initially diagnosed as multiple sclerosis. The authors highlight that unlike sporadic small vessel disease, CADASIL often involves the corpus callosum which is a characteristic predilection site for multiple sclerosis. This may be one of the reasons that so many cases are misdiagnosed as multiple sclerosis. However as the authors point out oligoclonal bands in the cerebrospinal fluid are not usually present in CADASIL.

Although we have no specific treatment for CADASIL increasing evidence demonstrates that cardiovascular risk factors, particularly smoking and hypertension are associated with an increased rate of progression and earlier onset of stroke.^{2,7} Therefore recent European guidelines have highlighted the need for tight cardiovascular risk factor control in this group of patients.⁸

Although CADASIL is thought to be a rare disease with prevalence in the United Kingdom of 4 in 100000,⁹ recent evidence suggests the typical cysteine change in mutations involving a cysteine change are much more common than in the general population. This was first shown by a group in Leiden who analysed anonymous genome sequencing databases and showed population frequencies of about 1 in 1000 in Europe and even higher frequencies in the Far East.¹⁰ Recent studies have confirmed these findings in UK Biobank and shown that these mutations are associated with an increased risk of both stroke and dementia.¹¹ Why typical cysteine change in mutations cause severe symptomatic familial disease in some individuals, and are apparently asymptomatic in the community in others, remains unknown. Mutation possible factors include mutation site, modifying risk factors and modifying genes. Mutations in

Address for correspondence
Hugh Stephen Markus,
(email: hsm32@medschl.cam.ac.uk).

DOI <https://doi.org/10.1055/s-0043-1769618>.
ISSN 0004-282X.

received
March 18, 2023
accepted
March 20, 2023

© 2023. Academia Brasileira de Neurologia. All rights reserved.
This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (<https://creativecommons.org/licenses/by/4.0/>).
Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

the proximal EGF repeats have been associated with more severe disease than those in distal EGF repeats.^{12,13} In UK Biobank, mutations were more likely to be associated with symptomatic stroke and dementia in those who had higher Framingham cardiovascular risk scores,¹¹ suggesting cardiovascular risk factors act as modifying factors, as they appear to do in patients with severe symptomatic disease. Genetic studies have suggested that modified genes also affect clinical severity,¹⁴ and this is an area of current research interest.

Conflict of Interest

There is no conflict of interest to declare.

References

- Hack RJ, Rutten J, Lesnik Oberstein SAJ. CADASIL. 2000 Mar 15 [updated 2019 Mar 14]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle 1993–2023. PMID: 20301673
- Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. *Stroke* 2010;41(04):630–634
- Jolly AA, Nannoni S, Edwards H, Morris RG, Markus HS. Prevalence and Predictors of Vascular Cognitive Impairment in Patients With CADASIL. *Neurology* 2022;99(05):e453–e461
- Nogueira R, Couto CM, Oliveira P, Martins BJAF, Montanaro VVA. Clinical and epidemiological profiles from a case series of 26 Brazilian CADASIL patients. *Arq Neuropsiquiatr* 2023;81(05):417–425
- Kang CH, Kim YM, Kim YJ, et al. Pathogenic *NOTCH3* Variants Are Frequent Among the Korean General Population. *Neurol Genet* 2021;7(06):e639
- Markus HS, Martin RJ, Simpson MA, et al. Diagnostic strategies in CADASIL. *Neurology* 2002;59(08):1134–1138
- Peters N, Holtmannspötter M, Opherk C, et al. Brain volume changes in CADASIL: a serial MRI study in pure subcortical ischemic vascular disease. *Neurology* 2006;66(10):1517–1522
- Mancuso M, Arnold M, Bersano A, et al. Monogenic cerebral small-vessel diseases: diagnosis and therapy. Consensus recommendations of the European Academy of Neurology. *Eur J Neurol* 2020;27(06):909–927
- Narayan SK, Gorman G, Kalaria RN, Ford GA, Chinnery PF. The minimum prevalence of CADASIL in northeast England. *Neurology* 2012;78(13):1025–1027
- Rutten JW, Dauwerse HG, Gravesteijn G, et al. Archetypal *NOTCH3* mutations frequent in public exome: implications for CADASIL. *Ann Clin Transl Neurol* 2016;3(11):844–853
- Cho BPH, Harshfield EL, Al-Thani M, Tozer DJ, Bell S, Markus HS. Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke. *JAMA Neurol* 2022;79(12):1303–1311
- Rutten JW, Van Eijsden BJ, Duering M, et al. The effect of *NOTCH3* pathogenic variant position on CADASIL disease severity: *NOTCH3* EGFr 1–6 pathogenic variant are associated with a more severe phenotype and lower survival compared with EGFr 7–34 pathogenic variant. *Genet Med* 2019;21(03):676–682
- Cho BPH, Jolly AA, Nannoni S, Tozer D, Bell S, Markus HS. Association of *NOTCH3* Variant Position With Stroke Onset and Other Clinical Features Among Patients With CADASIL. *Neurology* 2022;99(05):e430–e439
- Opherk C, Peters N, Holtmannspötter M, Gschwendtner A, Müller-Myhsok B, Dichgans M. Heritability of MRI lesion volume in CADASIL: evidence for genetic modifiers. *Stroke* 2006;37(11):2684–2689